Patent ID: 8802143

Claim:
A method for treating a patient suffering from dementia or Alzheimer's disease comprising: administering to the patient an oral dosage formulation as defined in Table 1 or 2, wherein the formulation provides an average blood level C max of memantine in a range of about 10-24 ng/mL during an average T max of about 10-45 hours, and an average blood level C max of donepezil in a range of about 12-38 ng/mL during an average T max of less than about 4 hours; TABLE 1 Ingredients Weight, mg Sustained Release (SR) Pellet-1 Formulation microcrystalline cellulose 100 Memantine HCl 20 hydroxypropyl methyl cellulose 6.0 Polyethylene glycol 0.6 Subtotal 126.6 SR-Coating-1 Formulation microcrystalline cellulose 31.7 Talc 31.7 hydroxypropyl methyl cellulose 0.8 Total 190.7 Immediate Release (IR) Granule-1 Formulation Donepezil HCl 10 microcrystalline cellulose 115 Pre-gelatinized starch 15 Total 140 IR/SR Tablet-1 Formulation SR Pellet-1/SR-Coating-1 190 IR Granule-1 140 polyvinyl polypyrrolidone 10 Magnesium Stearate 2 Total 342 TABLE 2 Ingredients Weight, mg SR Pellet-2 Formulation Polymethyl methacrylate 100 Memantine HCl 20 hydroxypropyl methyl cellulose 6.0 Polyethylene glycol 0.6 Subtotal 126.6 SR-Coating-2 Formulation microcrystalline cellulose 22.3 Ethyl cellulose 3.0 TiO 2 5.6 hydroxypropyl methyl cellulose 0.6 Total 158.1 IR Granule-2 Formulation Donepezil HCl 10 microcrystalline cellulose 115 Pre-gelatinized starch 15 Total 140 IR/SR Tablet-2 Formulation SR Pellet-2/SR-Coating-2 158 IR Granule-2 140 polyvinyl polypyrrolidone 10 Magnesium Stearate 2 Total 310.